Novartis is buying Myricx to internalize an NMTi-based ADC payload platform intended to expand ADC applicability and ...
Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 ...
It is also why I have spent over fifteen years building around a conviction the healthcare industry still resists: when ...
Troutman Pepper Locke senior associate Ryan Last explains when markets will start to significantly react to the upcoming pharma tariffs. In April of this year, President Trump announced plans to ...
Medicare GLP-1 Bridge provides Wegovy to eligible beneficiaries for $50/month through 2027, creating a defined access channel for obesity treatment previously largely excluded from Medicare coverage.
QuantumCell received worldwide rights to NeuroRestore/ACD856, with closing contingent on foreign direct investment approvals in Sweden and Denmark under customary regulatory conditions. Financial ...
Pharmaceutical Executive: How will targeted onshoring impact pharma’s domestic manufacturing? Ryan Last: Targeted reshoring ...
In today's Pharmaceutical Executive Daily, AlzeCure Pharma announces a collaboration with QuantumCell ApS worth more than $2.2 billion for global rights to its Neurostore platform including ...
FDA selected seven participants from 80+ requests using a scoring rubric emphasizing supply need, facility development stage, time-to-market, and manufacturing innovation. Amneal will make sterile ...
A July 17 response deadline requires documentation of trial-site governance in China, emphasizing due diligence, data protection controls, and monitoring of compliance at Xinjiang and PLA-affiliated ...
Proposed 100% tariffs target branded pharma imports, with a July 31, 2026 window to negotiate onshoring agreements that could reduce the rate to 20%. Exemptions may apply through MFN-negotiated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results